Although application of multiple safety measures like donor screening and screening for infectious agents has made blood transfusion safer than ever, blood safety remains a hot topic in transfusion medicine. Emerging pathogens constantly threaten the safety of blood and current safety measures have their limitations in addressing these matters. Pathogen reduction technologies have been developed as a proactive approach to overcoming these limitations. This paper outlines the efficacy of pathogen reduction technologies that are currently applied for platelets for clinical use. Their clinical efficacy and safety issues and other effects are also reviewed.
Blood Safety ; Blood Transfusion ; Donor Selection ; Mass Screening ; Transfusion Medicine

Lung transplantation has become the standard of care for select patients with advanced lung diseases of various etiologies. A relatively scarce donor pool limits wider application of lung transplantation. Donor selection criteria, donor management protocols, and improvement in postoperative management have lead to improved overall survival with a median survival rate of 5.7 years. Bilateral lung transplantation has become the procedure of choice for most indications due to significantly better long term survival, especially in patients younger than 60 years. Proper management of donor organs may increase the utilization rate of scarce organs and through the increasing number of lung transplantation and improvement in postoperative management, many patients on the waiting list may achieve a new life after lung transplantation with excellent quality of life and long term survival.
Donor Selection ; Humans ; Lung Diseases ; Lung Transplantation* ; Lung* ; Patient Selection ; Quality of Life ; Standard of Care ; Survival Rate ; Tissue Donors ; Waiting Lists

The primary goal in transfusion medicine is to promote high standards of quality in all aspects of transfusion, including production, management, and transfusion of blood components. To achieve this goal, a transfusion service quality management system should be established. Such a system should include several organizational structures, responsibilities, policies, processes, procedures, and resources with provided specifications and regulations. In this review, we summarize the current knowledge and practices regarding the quality management of hematology tests applied to the donor selection and production of blood components, including red blood cells, platelets, fresh frozen plasma, and cryoprecipitates in the field at blood centers.
Donor Selection ; Erythrocytes ; Hematology* ; Humans ; Plasma ; Social Control, Formal ; Tissue Donors ; Transfusion Medicine

PURPOSE: HLA (human leukocyte antigen)-class I genes are highly polymorphic, play many roles in organ and bone marrow transplantation. HLA-B is the most polymorphic class I locus with 414 alleles. HLA-class I typing, which is based on serologic method, has been used until recently. The development of molecular biological techniques make it possible to define the genotypes of HLA genes. METHODS: Analyses of HLA-B genotyping on 1,000 UCB (Umbilical Cord Blood) samples which were considered to be HLA-B homozygote or blank were performed by ARMS-PCR (Amplification Refractory Mutation System-PCR) method and direct sequencing. RESULTS: We could identify HLA-B*5001 which was known to be absent in Koreans. CONCLUSION: It is strongly suggested that HLA-B homozygote should be confirmed to the DNA level especially in cases of donor selection for the unrelated bone marrow transplantation.
Alleles ; Bone Marrow Transplantation ; DNA ; Donor Selection ; Fetal Blood ; Genotype ; HLA-B Antigens ; Homozygote ; Leukocytes

BACKGROUND: We found that intensive and long-term plasmapheresis might be responsible for iron depletion of donors in our previous study. So we examined 88 multi-time and 44 first-time donors to investigate the effects of long-term plasmapheresis on the iron status of the body. METHODS: Eighty eight donors who had never donated whole blood or donated plasma only regularly over a period of 5 years were selected. They were divided into group 1, 2 and 3 by donation interval and group A, B and C by the number of plasmapheresis per year. Fifty eight of them had follow-up data after the donation. Whole blood was taken from the donors before plasmapheresis by the Fenwal Autopheresis-C system. Each sample was assayed for serum ferritin, iron, TIBC and transferrin saturation. RESLUTS: For serum ferritin, iron, TIBC and transferrin saturation, the mean values of multi-time donors were in the normal range but significantly lower than those of first-time donors. Twenty four (27.3%) multi-time donors had either less than 10 ng/mL of serum ferritin or less than 16% of transferrin saturation. Six donors had the lower values of both serum ferritin and transferrin saturation. Among 88 multi-time donors, there were significant differences between groups. Group 1 with the shortest donation interval had significantly lower ferritin value than the other groups. Group C with the highest donation frequency had significantly lower ferritin, TIBC and transferrin saturation values than the other groups. The results for the follow-up data of 58 donors were similar to those for the initial data. CONCLUSION: The donation intervals and the frequency of plasmapheresis influence body iron status of donors. So intensive and long-term plasmapheresis may result in iron depletion in donors. Consequently, a more sophisticated donor screening system to prevent iron depletion in intensive and long-term plasmapheresis donors should be established.
Donor Selection ; Ferritins ; Follow-Up Studies ; Humans ; Iron* ; Plasma ; Plasmapheresis* ; Reference Values ; Tissue Donors* ; Transferrin

There has been continuous effort to prevent transfusion-transmitted infection (TTI). Strategies to prevent TTI can be divided into two components: first, determining donor eligibility, and second, managing bacterial contamination of blood products. To determine donor eligibility, medical history taking and screening tests for infectious diseases should be performed. To prevent bacterial contamination, blood collection process should be aseptic, tests for bacterial detection should be performed, and an application of pathogen reduction technology should also be considered. In this review, screening test items and methods, including nucleic acid amplification tests for determining donor eligibility, and precautions for blood collection, bacterial detection methods, and pathogen reduction technology for the prevention of bacterial contamination of blood products were discussed in detail.
Communicable Diseases ; Donor Selection ; Humans ; Mass Screening ; Medical History Taking ; Nucleic Acid Amplification Techniques ; Tissue Donors

OBJECTIVETo establish and evaluate the methods of internal quality control in blood donor screening by nucleic acid test (NAT).

METHODSAfter HBV-DNA standard quality control (QC) sample (60 IU/ml) was diluted by pooling 6 samples, the concentration was 10.0 IU/ml, which was approach twice of the low limit. When the pooling result turned out reactive, the pooling samples need to be split into single sample to process. Meanwhile, the standard QC samples were tested as well. The same batch QC samples were tested 20 times respectively, calculate the mean (x̄), standard deviation (SD) and CV. Make Levey-Jennings QC curves by setting x̄±2SD as warning, x̄±3SD as rejected. The Levey-Jennings quality controls chart was mapped by using Microsoft Excel.

RESULTSAfter 20 times test of mixed/split samples, the x̄±2SD were 33.03±1.47 and 30.08±0.98, the x̄±3SD were 33.03±2.20 and 30.08±1.47, the CV were 2.22% and 1.63%, respectively. The P value of t test was 0.08 and 0.17 respectively, there was no statistically significant difference between the 2 group.

CONCLUSIONWhen establish an internal QC system in the screening laboratory by nucleic acid testing, the concentration of the QC samples should be equal to normal specimens. This type of QC system may validate the extraction and amplification of the nucleic acid, and improve the stability of the test results.

BACKGROUND: Over the past several years, Clostridium difficile has become a major healthcare-associated pathogen. Fecal bacteriotherapy has been reported as an effective intervention for treating recurrent C. difficile infection by restoring the normal intestinal microbiota. METHODS: Articles on fecal bacteriotherapy were collected through PubMed, CINAHL, Cochrane Library, and Web of Science databases using the keywords "Clostridium difficile," "feces," "fecal transplantation," "fecal microbiota transplantation," and "fecal bacteriotherapy." Using a systematic literature review, variables of interest from articles that met the inclusion criteria were extracted and summarized. RESULTS: Among 141 articles that were published in English from January 1, 2000 to August 31, 2012, 8 studies were selected for analysis after assessing the titles, abstracts, and full contents. Fecal bacteriotherapy procedures varied with respect to donor selection, screening, infusion route, and preparation of the suspension. Donors were mostly family members or relatives, and donor screening included tests for blood borne and stool pathogens. Selected infusion routes were colonoscopy (62.5%), nasogastric tube (25%), and enema (12.5%). The success rate was reported to be 73-100%. There was a lack of a standard procedure for fecal bacteriotherapy in all of the selected studies. CONCLUSION: Fecal bacteriotherapy is an effective intervention for combating C. difficile infection that has a high success rate and no adverse effects. This therapy would be helpful for infection control in hospital settings by facilitating early eradication of C. difficile infection.
Clostridium ; Clostridium difficile ; Colonoscopy ; Donor Selection ; Enema ; Feces ; Humans ; Infection Control ; Mass Screening ; Metagenome ; Tissue Donors

BACKGROUND: In the Korean Red Cross Blood Center, ABO blood typing are routinely performed only via red cell grouping at blood donations sites. However, when an error occurs in this process, it is impossible to issue a blood product contrary to the result of the blood type of the Blood Laboratory Center, thereby resulting in delayed supply. Therefore, efforts are needed to reduce typing errors at blood donation sites. METHODS: We analyzed 656,786 donor screenings between January 1, 2016 and December 31, 2016;we also analyzed the statistical data of donor ABO typing between 2013 and 2015. To reduce ABO typing error, we notified and trained nurses at Busan, Gyeongnam, Ulsan, and Daegu-Gyeongbuk Blood centers in June, 2016. We tried to confirm the improvement of ABO typing error at blood donation sites by comparing ABO typing before and after training. For data comparison, chi-square test was conducted (95% confidence interval, 0.05 significant level). RESULTS: The blood typing error rate was significantly lower (P=0.003) four months after training (0.005%) than before training (0.015%), and the blood typing error rate was significantly higher for the first blood donor (P<0.001). CONCLUSION: Educational training for nurses at blood donation sites may be effective in reducing ABO typing error. Continuous and regular training seems to be needed in future to reduce ABO typing error.
Blood Donors* ; Blood Grouping and Crossmatching* ; Busan ; Donor Selection ; Humans ; Red Cross ; Tissue Donors ; Ulsan

BACKGROUND: The current donor selection criteria need to be revised to ensure a reliable blood supply and for donor protection. This study was conducted to analyze the distribution of hemoglobin (Hb) levels of blood donors and to estimate the change of eligible donors when using the revised Hb criterion. METHODS: The Hb levels of all the blood donors who visited the Korean Red Cross Blood Center (KRCBC) between November 9th, 2010 and November 15th, 2010 were measured with a portable hemoglobinometer (HemoCue). The Hb levels of all the eligible donors and some of the deferred donors who visited the Hanmaeum Blood Center (HBC) from April 26th, 2010 to April 30th, 2010 and from November 9th, 2010 to November 15th, 2010 were measured with a portable hemoglobinometer (Hemo_Control). RESULTS: A total of 7,521 donors (6,500 eligible donors and 1,021 deferred donors) were enrolled. The donation eligibility rate at the KRCBC, which is where all the donors were examined, was 84.2% (3,409/4,049) and the deferral rate was 15.8% (640/4,049). The percent of blood donors whose Hb level was less than 12.5 g/dL was 2.1% of the men (44/2,145) and 34.9% of the women (664/1,904), respectively. The percent of female deferred donors with a Hb level of 12.0~12.4 g/dL was 19.3% (109/564) and the percent of male eligible donors with a Hb level of 12.5~12.9 g/dL was 2.6% (54/2,069). At the HBC, and with some deferred donors being excluded, the deferral rate of males and females was 2.0% (36/1,799) and 20.6% (345/1,673), respectively. CONCLUSION: About 20% of the female deferred donors could be expected to participate when a less strict Hb criterion (> or =12.0 g/dL) is applied. This study is thought to be helpful in order to determine the number of donors according to the Hb criteria and to create improved criteria.
Blood Donors ; Dietary Sucrose ; Donor Selection ; Female ; Hemoglobins ; Humans ; Male ; Red Cross ; Tissue Donors